Agalsidase beta
Brand names: Fabrazyme
Agalsidase beta is an enzyme replacement therapy used for the long-term treatment of Fabry disease, an inherited lysosomal storage disorder.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a recombinant form of human alpha-galactosidase A that replaces the deficient enzyme and catalyses the breakdown of globotriaosylceramide that accumulates in Fabry disease.
Prescribing in practice
- Infusion-associated reactions are common, so administer under specialist supervision with facilities to manage hypersensitivity, premedicating where appropriate.
- It is given by regular intravenous infusion as lifelong treatment within a specialist Fabry service.
- Antibody formation can occur and may affect response; evaluate tolerability and disease control over time as set out in the SPC.
Monitoring
Monitor for infusion reactions during administration and review cardiac, renal and overall disease progression periodically within the specialist service.
Counselling the patient
- Report flushing, fever, chills, itching or breathlessness during your infusion straight away.
- Keep to your scheduled infusions and specialist reviews so treatment can be monitored.
- Carry details of your diagnosis and treatment for emergencies.
Evidence & guidelines
Use of enzyme replacement therapy for Fabry disease is guided by specialist commissioning and lysosomal storage disorder service protocols.
Reference: NHS England LSDU; SmPC Fabrazyme; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- C-Peptide to Glucose Ratio · Diabetes Classification
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
- Revised ISS (R-ISS) for Multiple Myeloma · Haematological Malignancy
- International Staging System for Multiple Myeloma (ISS) · Oncology